GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » Common Stock

Predilife (XPAR:ALPRE) Common Stock : €0.09 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Predilife Common Stock?

Predilife's quarterly common stock stayed the same from Jun. 2022 (€0.09 Mil) to Dec. 2022 (€0.09 Mil) and stayed the same from Dec. 2022 (€0.09 Mil) to Jun. 2023 (€0.09 Mil).

Predilife's annual common stock increased from Dec. 2020 (€0.09 Mil) to Dec. 2021 (€0.09 Mil) but then stayed the same from Dec. 2021 (€0.09 Mil) to Dec. 2022 (€0.09 Mil).


Predilife Common Stock Historical Data

The historical data trend for Predilife's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife Common Stock Chart

Predilife Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Common Stock
Get a 7-Day Free Trial 0.07 0.07 0.09 0.09 0.09

Predilife Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.09 0.09 0.09 0.09

Predilife Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Predilife (XPAR:ALPRE) Business Description

Traded in Other Exchanges
N/A
Address
114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800
Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines